On August 19, 2025 Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, reported that the Company will host a virtual Stakeholder Briefing on August 27, 2025 at 4:00 p.m. ET (Press release, Agenus, AUG 19, 2025, View Source [SID1234655375]). The event will feature presentations from senior management and industry thought leaders, offering insights into transformative developments that could shape the future of cancer treatment. The agenda includes a strategic and financial overview, achievements tied to the Zydus partnership closing, patient needs fueling interest in colorectal cancer (CRC) studies, recent data from the botensilimab (BOT) and balstilimab (BAL) program, and an overview of the Phase 3 BATTMAN study in metastatic CRC—plus highlights of upcoming milestones and potential breakthroughs in immuno-oncology. The session will conclude with a live Q&A.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Speakers to Include:

Garo H. Armen, PhD
Founder, Chairman, CEO of Agenus

Jennifer Buell, PhD
CEO of MiNK Therapeutics/ Chair of Executive Committee of Agenus

Richard M. Goldberg, MD
Chief Development Officer of Agenus (joined May 2025)
GI oncology expert with 40+ years in CRC research

Nicholas C. DeVito, MD
Assistant Professor of Medical Oncology at Duke University
Primarily treats patients with CRC and gastroesophageal cancers
Research focused on tumor immune evasion and immunotherapy

Chris O’Callaghan, DVM, MSc, PhD, & Jonathan Loree, MD, MS, FRCPC (CCTG):
Senior Investigators at Canadian Cancer Trials Group (CCTG)

Stakeholder Briefing Details:

Webcast Link | View Source

Audience Conference Call Registration Link | View Source

Conference ID: 73242